ArticleVaccine: X2020
Roadmap for strengthening the vaccine supply chain in emerging countries: Manufacturers' perspectives.
Article in Vaccine: X, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The resurgence of monkeypox virus: a critical global health challenge and the need for vigilant intervention.Frontiers in public health · 2025Review
- Current State and Challenges of Local Production of Vaccines in Nigeria.Public health challenges · 2024Article
- Vaccine traceability: Key learnings from the supply chain initiative by manufacturers from emerging countries.Vaccine: X · 2023Article
- mRNA vaccine in cancer therapy: Current advance and future outlook.Clinical and translational medicine · 2023Review
- VaccineChain: A checkpoint assisted scalable blockchain based secure vaccine supply chain with selective revocation.Journal of Industrial Information Integration · 2023Article
- Blockchain and COVID-19 pandemic: applications and challenges.Cluster computing · 2023Review
- Modeling a sustainable vaccine supply chain for a healthcare system.Journal of cleaner production · 2022Article
- Article
- Article
- COVID-19 pandemics Stage II - Energy and environmental impacts of vaccination.Renewable & sustainable energy reviews · 2021Review
- Advancing sustainable development goals through immunization: a literature review.Globalization and health · 2021Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Manufacturers have a significant stake in the vaccine supply chain as their reputations rest on the effectiveness of their vaccines at the point of vaccination. The risks of low performing supply chains are detrimental for the safety and effectiveness of vaccines, with potential consequences to future supply in the case of adverse events. For this reason, a study was set up to explore the involvement of developing country manufacturers in the vaccine supply chain over the next decade to determine the areas where innovations could have a positive impact on the supply chain, focusing on the secondary stages of production where formulation, filling and packaging take place. An expert desk review identified eight areas of interest for the vaccine supply chain and informed the development of a survey to assess the relevance of the areas identified. The review also conjectured whether the overall effect of the identified areas is cost-neutral or resulting in net savings to countries. Overall, respondents identified five areas as of highest interest and subsequently an expert working group of representative manufacturers prioritized three of them. Specifically, traceability in the context of global digital health initiatives, stockpiling in the context of addressing vaccine shortages, stock-outs, outbreaks and epidemic prevention, and new packaging technologies are discussed in this report. It is important that vaccine manufacturers be actively engaged in global stakeholders' forums, as equal partners in determining the best ways for improving the vaccine supply chain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.